Immune Senescence in the Elderly: Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages
The immune system is central to human health and its impairment can have serious consequences. One of the hallmarks of aging is the progressive loss of immune function exposing older people to increased risk from infectious diseases that would not normally be more than an inconvenience. This project will use state-of-the-art technology developed by the Stanford Human Immune Monitoring Center to survey older individuals for signs of immune system aging and to gather information about the factors associated with the decline of immune function.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : Trivalent inactivated influenza vaccine (TIV)
Phase: Phase 4
Ages Eligible For Study:
- Prior participant in Years 1, 2, and/or 3 of this study - Age 18-30, 60-79, or 80-100 years, inclusive at time of initial enrollment - General good health and ambulatory at time of enrollment - No acute illness at time of vaccination - Willing and able to sign Informed Consent - Available for follow-up for the planned duration of the study - Acceptable medical history by screening evaluation and brief clinical assessment - All female subjects of childbearing potential must use an acceptable method of contraception and not become pregnant for the duration of the clinical phase of the study (approximately 1 month to completion of Visit 3). (Acceptable contraception may include implants, injectables, combined oral contraceptives, effective intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner).
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305